Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- S-3 Shelf registration
- 4.1 EX-4.1
- 4.2 EX-4.2
- 4.3 EX-4.3
- 4.4 EX-4.4
- 5.1 EX-5.1
- 5.2 EX-5.2
- 5.3 EX-5.3
- 5.4 EX-5.4
- 12.1 EX-12.1
- 25.1 EX-25.1
- 25.2 EX-25.2
- 25.3 EX-25.3
- 25.4 EX-25.4
- 25.5 EX-25.5
- 25.6 EX-25.6
- 25.7 EX-25.7
- 25.8 EX-25.8
- 25.9 EX-25.9
- 25.10 EX-25.10
- 25.11 EX-25.11
- 25.12 EX-25.12
- 25.13 EX-25.13
- 25.14 EX-25.14
- 25.15 EX-25.15
- 25.16 EX-25.16
- 25.17 EX-25.17
- 25.18 EX-25.18
- 25.19 EX-25.19
- 25.20 EX-25.20
- 25.21 EX-25.21
- 25.22 EX-25.22
Teva Pharmaceutical Finance IV similar filings
Filing view
External links
Exhibit 12.1
COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES
Year Ended December 31, | ||||||||||||||||||||
2017 | 2016 | 2015 | 2014 | 2013 | ||||||||||||||||
(U.S. dollars in millions, except ratios) | ||||||||||||||||||||
Earnings | ||||||||||||||||||||
Pre-tax income from continuing operations before adjustments for minority interests in consolidated subsidiaries or income or loss from equity investments | 824 | 2,352 | 3,638 | 1,250 | ||||||||||||||||
Fixed charges, as below | 559 | 283 | 336 | 340 | ||||||||||||||||
Interest capitalized, less amortization of capitalized interest | (1 | ) | (2 | ) | (3 | ) | (3 | ) | ||||||||||||
|
|
|
|
|
|
|
|
|
| |||||||||||
Total | 1,383 | 2,633 | 3,971 | 1,587 | ||||||||||||||||
|
|
|
|
|
|
|
|
|
| |||||||||||
Fixed Charges | ||||||||||||||||||||
Interest costs (expensed and capitalized) and amortization of issuance costs relating to long-term debentures | 504 | 242 | 285 | 301 | ||||||||||||||||
Rentals –one-third of rental expenses | 55 | 41 | 51 | 39 | ||||||||||||||||
|
|
|
|
|
|
|
|
|
| |||||||||||
Total | 559 | 283 | 336 | 340 | ||||||||||||||||
|
|
|
|
|
|
|
|
|
| |||||||||||
Ratio of Earnings to Fixed Charges | 2.5 | 9.3 | 11.8 | 4.7 |